[go: up one dir, main page]

ATE201990T1 - Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren - Google Patents

Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Info

Publication number
ATE201990T1
ATE201990T1 AT94909927T AT94909927T ATE201990T1 AT E201990 T1 ATE201990 T1 AT E201990T1 AT 94909927 T AT94909927 T AT 94909927T AT 94909927 T AT94909927 T AT 94909927T AT E201990 T1 ATE201990 T1 AT E201990T1
Authority
AT
Austria
Prior art keywords
inclusion complexes
pct
date
ranitidine
hxdrochloride
Prior art date
Application number
AT94909927T
Other languages
English (en)
Inventor
Wilfried Fischer
Karin Klokkers
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Application granted granted Critical
Publication of ATE201990T1 publication Critical patent/ATE201990T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT94909927T 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren ATE201990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9306024 1993-03-05
PCT/EP1994/000645 WO1994020091A1 (en) 1993-03-05 1994-03-04 Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation

Publications (1)

Publication Number Publication Date
ATE201990T1 true ATE201990T1 (de) 2001-06-15

Family

ID=10984320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909927T ATE201990T1 (de) 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Country Status (10)

Country Link
US (1) US5665767A (de)
EP (1) EP0687174B1 (de)
JP (1) JPH09502698A (de)
AT (1) ATE201990T1 (de)
CA (1) CA2157190A1 (de)
CZ (1) CZ224995A3 (de)
DE (1) DE69427467T2 (de)
RU (1) RU2143896C1 (de)
WO (1) WO1994020091A1 (de)
ZA (1) ZA941544B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768897A1 (de) * 1994-07-06 1997-04-23 Farmarc Nederland B.V. Inklusion-komplexe von ranatidine
PL193229B1 (pl) * 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
AU1513699A (en) * 1998-08-18 2000-03-14 Nikolai Borisovich Leonidov Physically stable and x-ray amorphous form of hydrochloride ranitidine having anincreased antitumoral activity and method for producing the same
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US20040202694A1 (en) * 2003-04-11 2004-10-14 Vascular Control Systems, Inc. Embolic occlusion of uterine arteries
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CN101123989B (zh) * 2004-08-02 2010-12-15 奇斯药制品公司 制备吡罗昔康:β-环糊精包合物的方法
CN101056538A (zh) * 2004-09-27 2007-10-17 嘉吉公司 环糊精包合复合物和其制备方法
US8722684B2 (en) 2006-06-16 2014-05-13 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
US8889243B2 (en) 2012-08-16 2014-11-18 3M Innovative Properties Company Mechanical fastening nets and methods of making the same
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity
CA3167273A1 (en) * 2020-03-19 2021-09-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stabilization of compounds as cyclodextrin complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione

Also Published As

Publication number Publication date
EP0687174A1 (de) 1995-12-20
WO1994020091A1 (en) 1994-09-15
JPH09502698A (ja) 1997-03-18
EP0687174B1 (de) 2001-06-13
ZA941544B (en) 1994-10-31
RU2143896C1 (ru) 2000-01-10
DE69427467T2 (de) 2002-06-06
CZ224995A3 (en) 1995-12-13
US5665767A (en) 1997-09-09
DE69427467D1 (de) 2001-07-19
CA2157190A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
ATE201990T1 (de) Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
EP1181013A4 (de) Verfahren und zusammansetzung zur behandlung von krebs
ATE319480T1 (de) Acylierte zyklodextrin guest-inklusion komplexe
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
DE60112609D1 (en) Pyrazolopyridine
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
DE69428334D1 (de) Wässrige Lösungen enthaltend Inklusionskomplexe aus Benzothiophenderivaten und Cyclodextrinen
GT200000103A (es) Trifluorbutenos nematocidas.
NO996053L (no) Parfymerte en- og to-fase blandinger for å redusere kroppslukt, samt fremgangsmåte ved anvendelse derav
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BR9808396A (pt) Processo para aumentar a deposição de um agente benéfico de uma composição em barra, e, barra
ES2243579T3 (es) Derivados de pirazolopirideno.
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE229340T1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
DE69906345D1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
DE69412760D1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
ATE273987T1 (de) Neue fucosylierte oligosaccharide und verfahren zu deren herstellung
DE10193689D2 (de) Retardpartikeldispersion
IT1241673B (it) Complessi di inclusione di silibinina con ciclodestrina, loro preparazione e composizioni farmaceutiche che li contengono.
IT1304183B1 (it) Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici.
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties